Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?

Thura Win Htut; Kyaw Zin Thein; Kyaw Lwin Aung; Thein Hlaing Oo

doi:10.1007/s00520-022-07138-8

Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?

Thura Win Htut, Kyaw Zin Thein, Kyaw Lwin Aung, Thein Hlaing Oo

Research output: Contribution to journal › Article › peer-review

Abstract

Thrombosis is the second leading cause of death in cancer patients. Patients with pancreatic cancer (PC) have a very high risk of developing venous thromboembolism (VTE). Even though primary ambulatory thromboprophylaxis (PATP) could decrease this risk, there are uncertain issues with regard to the choice and dose of anticoagulants, duration of anticoagulant therapy, and patient selection criteria. In addition, the current practice guidelines on PATP in PC patients are equivocal. This review critically appraises the evidence on the use of PATP in PC patients receiving chemotherapy.

Original language	English (US)
Pages (from-to)	8511-8517
Number of pages	7
Journal	Supportive Care in Cancer
Volume	30
Issue number	10
DOIs	https://doi.org/10.1007/s00520-022-07138-8
State	Published - Oct 2022

Keywords

Chemotherapy
Pancreatic cancer
Primary ambulatory thromboprophylaxis
Risk scoring systems
Venous thromboembolism

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s00520-022-07138-8

Cite this

@article{37a87f1dc8cd421ba0e511c3b10fbe1a,

title = "Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?",

abstract = "Thrombosis is the second leading cause of death in cancer patients. Patients with pancreatic cancer (PC) have a very high risk of developing venous thromboembolism (VTE). Even though primary ambulatory thromboprophylaxis (PATP) could decrease this risk, there are uncertain issues with regard to the choice and dose of anticoagulants, duration of anticoagulant therapy, and patient selection criteria. In addition, the current practice guidelines on PATP in PC patients are equivocal. This review critically appraises the evidence on the use of PATP in PC patients receiving chemotherapy.",

keywords = "Chemotherapy, Pancreatic cancer, Primary ambulatory thromboprophylaxis, Risk scoring systems, Venous thromboembolism",

author = "Htut, {Thura Win} and Thein, {Kyaw Zin} and Aung, {Kyaw Lwin} and Oo, {Thein Hlaing}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2022",

month = oct,

doi = "10.1007/s00520-022-07138-8",

language = "English (US)",

volume = "30",

pages = "8511--8517",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy

T2 - hope or hype?

AU - Htut, Thura Win

AU - Thein, Kyaw Zin

AU - Aung, Kyaw Lwin

AU - Oo, Thein Hlaing

PY - 2022/10

Y1 - 2022/10

N2 - Thrombosis is the second leading cause of death in cancer patients. Patients with pancreatic cancer (PC) have a very high risk of developing venous thromboembolism (VTE). Even though primary ambulatory thromboprophylaxis (PATP) could decrease this risk, there are uncertain issues with regard to the choice and dose of anticoagulants, duration of anticoagulant therapy, and patient selection criteria. In addition, the current practice guidelines on PATP in PC patients are equivocal. This review critically appraises the evidence on the use of PATP in PC patients receiving chemotherapy.

AB - Thrombosis is the second leading cause of death in cancer patients. Patients with pancreatic cancer (PC) have a very high risk of developing venous thromboembolism (VTE). Even though primary ambulatory thromboprophylaxis (PATP) could decrease this risk, there are uncertain issues with regard to the choice and dose of anticoagulants, duration of anticoagulant therapy, and patient selection criteria. In addition, the current practice guidelines on PATP in PC patients are equivocal. This review critically appraises the evidence on the use of PATP in PC patients receiving chemotherapy.

KW - Chemotherapy

KW - Pancreatic cancer

KW - Primary ambulatory thromboprophylaxis

KW - Risk scoring systems

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85130481388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130481388&partnerID=8YFLogxK

U2 - 10.1007/s00520-022-07138-8

DO - 10.1007/s00520-022-07138-8

M3 - Article

C2 - 35579754

AN - SCOPUS:85130481388

SN - 0941-4355

VL - 30

SP - 8511

EP - 8517

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 10

ER -

Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this